Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
Bcl-2
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
27 views | Sep 26 2021
Dongyan Liu et al. found that the assessment of BAK/MCL1 complexes might be useful for predicting response to paclitaxel alone or in combination with BH3 mimetics. [Read the Full Post]
Verticillin A increases the BIM EL/MCL-1 ratio to overcome ABT-737-resistance in human colon cancer cells by targeting the MEK/ERK pathway
75 views | Aug 08 2021
Yuelin Guan et al. suggested the potential application of Verticillin A as a MEK inhibitor in BH3-mimetic-based therapy. [Read the Full Post]
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia
54 views | Jul 29 2021
Emma M Carrington et al. showed a differential survival requirement in activated neutrophils for BCL-XL and revealed a new therapeutic approach to neutrophil-mediated diseases. [Read the Full Post]
Identification of autophagy-related genes as targets for senescence induction using a customizable CRISPR-based suicide switch screen
51 views | Jun 27 2021
Arnout Schepers et al. presented a suicide switch system that allowed genome-wide CRISPR screening in growth-arrested subpopulations by eliminating the proliferating cells during the screen through activation of a suicide switch in proliferating cells. [Read the Full Post]
Structure-Based Design of A-1293102, a Potent and Selective BCL-X L Inhibitor
47 views | Jun 25 2021
Zhi-Fu Tao et al. thought that A-1293102 represented one of the few distinct structural series of selective BCL-XL inhibitors, and thus served as a useful tool for biological studies as well as a lead compound for further optimization. [Read the Full Post]
Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia
59 views | Jun 24 2021
Ana Colado et al. showed that the IgM/IgA enriched preparation not only affected relevant mechanisms involved in CLL pathogenesis but also had a particular profile of immunomodulatory effects on T cells that deserved further investigation. [Read the Full Post]
Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model
72 views | May 12 2021
Yeu-Sheng Tyan et al. found the synergistic effects of orlistat combined with enzalutamide in vitro and castration in vivo on human prostate cancer. [Read the Full Post]
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition
51 views | May 05 2021
Bing Z Carter et al. found that co-targeting MCL-1 and BCL-2 improved the efficacy of and overcame preexisting and acquired resistance to BCL-2 inhibition. [Read the Full Post]
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor
55 views | May 04 2021
Zoltan Szlavik et al. reported the discovery of clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. [Read the Full Post]
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
52 views | May 04 2021
Nabanita Mukherjee et al. suggested that several pro-apoptotic BCL2 family members, BCL2-like 11 (apoptosis facilitator) (BIM), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) or BID, played a role in the combination-induced effects. [Read the Full Post]
